All In Biotech

Drug Trial Radar · NCT07765888

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED PHASE 3 COMBINATION THERAPY STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE OR OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 375 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

375

Planned (sponsor's estimate)

Start

Aug 17, 2026

Primary completion

Mar 10, 2028

Study completion Jun 2, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema (also called atopic dermatitis) is a common skin condition that makes the skin dry, itchy, red, and irritated. * This study is seeking participants who: Are aged 12 years or older. * Were confirmed to have atopic dermatitis (AD) at least 12 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. Participants in this study will randomly receive either tilrekimig or placebo at a 2:1 ratio. A placebo does not have any medicine in it but looks just like the medicine being studied. The study treatment period will be 24 weeks. The last dose of study treatment will be administered at week 20. Some participants will join the long-term extension study C4531008 at week 24. A long-term extension study is an additional study that participants may be able to join after completing the main study. It allows researchers to continue collecting information about how well the study medicine works and how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last study treatment dose.

Conditions

  • Atopic Dermatitis

Interventions

  • TilrekimigDrug

    Subcutaneous Injections at required timepoints

  • PlaceboDrug

    Subcutaneous Injections at required timepoints

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in the proportion of Eczema and Severity Index (EASI)75 responders between tilrekimig versus placeboTime frame: Week 16
  2. Difference in the proportion of Validated Investigator Global Assessment (vIGA)-AD™ 0/1 responders between tilrekimig versus placeboTime frame: Week 16

Locations

23 sites in 3 countries. Site status is shown where the registry gives one.

  • Cahaba Dermatology & Skin Health Center

    Birmingham, Alabama · Recruiting

  • ORSO Health

    Scottsdale, Arizona · Recruiting

  • Kern Research, Inc.

    Bakersfield, California · Recruiting

  • First OC Dermatology Research Inc

    Fountain Valley, California · Not yet recruiting

  • Northridge Clinical Trials

    Northridge, California · Recruiting

  • University Clinical Trials, Inc

    San Diego, California · Recruiting

  • Focus Clinical Research

    West Hills, California · Not yet recruiting

  • Pediatric Skin Research

    Miami, Florida · Recruiting

  • AllerVie Clinical Research

    Panama City, Florida · Recruiting

  • GCP Research , Global Clinical Professionals

    St. Petersburg, Florida · Recruiting

  • Marietta Dermatology Clinical Research, Inc.

    Marietta, Georgia · Recruiting

  • Aeroallergy Research Laboratories of Savannah, Inc

    Savannah, Georgia · Recruiting

  • Red River Research Partners LLC

    Fargo, North Dakota · Recruiting

  • Derm Texas

    Dallas, Texas · Recruiting

  • Stryde Research-Epiphany Dermatology

    Southlake, Texas · Recruiting

  • Innovaderm Research Inc

    Montreal, Quebec, Canada · Recruiting

  • Charme Clinique

    Matsudo, Chiba, Japan · Recruiting

  • Miyata Dermatology Clinic

    Matsudo, Chiba, Japan · Recruiting

  • Shibaki Dermatology Clinic

    Teine-ku, Hokkaido, Japan · Not yet recruiting

  • Aile Home Clinic Nagaoka

    Nagaoka, Niigata, Japan · Recruiting

  • Osaka Metropolitan University Hospital

    Osaka, Osaka, Japan · Not yet recruiting

  • Dermatology and Ophthalmology Kume Clinic

    Sakai, Osaka, Japan · Recruiting

  • NTT Medical Center Tokyo

    Shinagawa, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.